Evotec and Exscientia announce start of human clinical trials of novel immuno-oncology drug

Hamburg, Germany, 09 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia’s next generation 3-D evolutionary AI-design platform, Centaur Chemist®. The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic side effects as well as minimal brain exposure to avoid potential undesired centrally-mediated side effects.

Tumour cells produce high levels of adenosine, a molecule that helps them escape immune system detection by binding to the A2a receptor on cancer-fighting T-cells, reducing T-cell ability to eliminate disease. Therefore, this highly selective A2a receptor antagonist is being investigated for its ability to prevent adenosine from binding to the T-cell receptor and potentially promote anti-tumour T-cell activity.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “We highly value our ongoing partnership with Exscientia, which has been highly collaborative and productive in every respect. We are therefore delighted to announce the start of clinical development of our co-owned A2a antagonist with Exscientia in the hope that the fruits of our collaboration can bring potential benefits to patients in the future.”

Prof. Andrew Hopkins, CEO and founder of Exscientia, said: “We set ambitious therapeutic objectives for this project, especially high selectivity for the A2a receptor and central nervous system (CNS) sparing properties, in order to reduce the likelihood of
potential side effects. Even with these challenging objectives, we were able to discover our
candidate molecule within 8 months of project initiation.”

Exscientia will lead further clinical development of the molecule and Evotec will retain co-
ownership rights throughout clinical development.

ABOUT EXSCIENTIA
Exscientia is an Artificial Intelligence (AI)-driven pharmatech committed to discovering and
designing the best possible medicines in the fastest and most effective manner. Exscientia is the first
company to progress AI-designed small molecules into the clinical setting and repeatedly
demonstrate the ability of AI to transform the way drugs are created. Drug design is precision
engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn
from the widest range of data and consistently reapply enhanced knowledge through iterations of
design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts
alone, candidate molecules satisfying complex therapeutic requirements are created with
revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best
ideas of science to rapidly become the best medicines for patients. For more information visit us on
www.exscientia.ai or follow us on Twitter @exscientiaAI.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly
progressing innovative product approaches with leading pharmaceutical and biotechnology
companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and
our more than 3,500 employees provide the highest quality stand-alone and integrated drug
discovery and development solutions. We cover all activities from target-to-clinic to meet the
industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The
Company has established a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas
including neuronal diseases, diabetes and complications of diabetes, pain and inflammation,
ocology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On
this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product
opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established
multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers
Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional
information please go to www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a
number of risks and uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are
beyond our control, and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or circumstances on which any such
statement is based.